keyword
MENU ▼
Read by QxMD icon Read
search

HDL HIV

keyword
https://www.readbyqxmd.com/read/29145807/durability-of-switch-regimens-based-on-rilpivirine-or-on-integrase-inhibitors-both-in-association-with-tenofovir-and-emtricitabine-in-hiv-infected-virologically-suppressed-patients
#1
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virologically suppressed, HIV-infected patients. METHODS: Retrospective analysis of patients who started rilpivirine or an InSTI (both with tenofovir and emtricitabine) with <50 HIV-RNA copies/mL and had at least one HIV-RNA assessed while receiving the study regimen...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29112070/switching-from-a-ritonavir-boosted-protease-inhibitor-to-a-dolutegravir-based-regimen-for-maintenance-of-hiv-viral-suppression-in-patients-with-high-cardiovascular-risk
#2
José M Gatell, Lambert Assoumou, Graeme Moyle, Laura Waters, Margaret Johnson, Pere Domingo, Julie Fox, Esteban Martinez, Hans-Jürgen Stellbrink, Giovanni Guaraldi, Mar Masia, Mark Gompels, Stephane De Wit, Eric Florence, Stefan Esser, François Raffi, Anton L Pozniak
OBJECTIVE: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. METHODS: HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. Patients were randomized to switch to DTG or to remain on PI/r. Primary endpoints were: proportion maintaining HIV RNA less than 50 copies per ml and percentage change from baseline of total cholesterol at week 48...
November 28, 2017: AIDS
https://www.readbyqxmd.com/read/29110385/vitamin-d-and-progression-of-carotid-intima-media-thickness-in-hiv-positive-canadians
#3
H Huff, A T Merchant, E Lonn, E Pullenayegum, F Smaill, M Smieja
OBJECTIVES: Based on a growing body of evidence implicating low vitamin D status in the development of cardiovascular disease (CVD), we hypothesized that in Canadian HIV-positive adults, low 25-hydroxyvitamin D (25(OH)D) concentration would be associated with increased subclinical vascular disease progression. METHODS: We prospectively studied the relationship between baseline 25(OH)D and subsequent progression of carotid intima-media thickness (CIMT) between 2002 and 2011, in the Canadian HIV Vascular Study using stored blood specimens...
November 6, 2017: HIV Medicine
https://www.readbyqxmd.com/read/29062178/role-of-lcat-and-apo-a-i-in-newly-diagnosed-hiv-patients
#4
Akshata Mirajkar, Shashikant Nikam, Padmaja Nikam, Giridhar Patil
Human immunodeficiency virus (HIV) infection is a growing concern for health workers. The two major components of dyslipidemia in HIV infected patients are hypertriglyceridemia and decreased levels of high density lipoprotein (HDL) which contribute to increased atherosclerotic risk. The study included 150 newly diagnosed HIV patients and 150 healthy controls. In all these cases Lecithin cholesterol acyl transferase (LCAT) activity was assessed by measuring the difference between esterified and free cholesterol by digitonin precipitation method and levels of Apolipoprotein A-I (apo A-I) were measured by immunoturbidimetric method...
October 2017: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/29020293/dual-therapy-with-darunavir-and-ritonavir-plus-lamivudine-versus-triple-therapy-with-darunavir-and-ritonavir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-or-abacavir-and-lamivudine-for-maintenance-of-hiv-1-viral-suppression-randomised-open-label-non
#5
Federico Pulido, Esteban Ribera, María Lagarde, Ignacio Pérez-Valero, Rosario Palacios, José A Iribarren, Antoni Payeras, Pere Domingo, José Sanz, Miguel Cervero, Adrián Curran, Francisco J Rodríguez-Gómez, María J Téllez, Pablo Ryan, Pilar Barrufet, Hernando Knobel, Antonio Rivero, Belén Alejos, María Yllescas, José R Arribas
Background: Our objective was to assess the therapeutic non-inferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression. Methods: 48-week, multicenter, open-label, non-inferiority trial (margin 12%). Patients with HIV-1 RNA <50 copies/mL for ≥6 months on triple therapy with darunavir/ritonavir and two nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine), with no resistance, were randomized to continue therapy (n=128) or switch to darunavir/ritonavir and lamivudine (n=129)...
August 17, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28993180/efficacy-and-safety-of-switching-from-boosted-protease-inhibitors-plus-emtricitabine-and-tenofovir-disoproxil-fumarate-regimens-to-single-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-at-48-weeks-in-adults-with-virologically-suppressed
#6
Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer
BACKGROUND: Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate. METHODS: EMERALD was a phase-3, randomised, active-controlled, open-label, international, multicentre trial, done at 106 sites across nine countries in North America and Europe...
October 5, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28980332/generalized-linear-mixed-model-for-binary-outcomes-when-covariates-are-subject-to-measurement-errors-and-detection-limits
#7
Xianhong Xie, Xiaonan Xue, Howard D Strickler
Longitudinal measurement of biomarkers is important in determining risk factors for binary endpoints such as infection or disease. However, biomarkers are subject to measurement error, and some are also subject to left-censoring due to a lower limit of detection. Statistical methods to address these issues are few. We herein propose a generalized linear mixed model and estimate the model parameters using the Monte Carlo Newton-Raphson (MCNR) method. Inferences regarding the parameters are made by applying Louis's method and the delta method...
October 5, 2017: Statistics in Medicine
https://www.readbyqxmd.com/read/28978797/antiinflammatory-effects-of-aprepitant-coadministration-with-cart-regimen-containing-ritonavir-in-hiv-infected-adults
#8
Sergei Spitsin, Pablo Tebas, Jeffrey S Barrett, Vasiliki Pappa, Deborah Kim, Deanne Taylor, Dwight L Evans, Steven D Douglas
BACKGROUND: HIV-infected individuals, even well controlled with combined antiretroviral therapy (cART), have systemic inflammation and comorbidities. Substance P (SP) is an undecapeptide, which mediates neurotransmission and inflammation through its cognate neurokinin 1 receptor (NK1R). Plasma SP levels are elevated in HIV-infected individuals. The FDA-approved antiemetic aprepitant, an NK1R antagonist, has anti-HIV effects and antiinflammatory actions. We evaluated the safety, pharmacokinetics, and antiinflammatory properties of aprepitant in HIV-positive individuals receiving cART...
October 5, 2017: JCI Insight
https://www.readbyqxmd.com/read/28964268/a-dual-regimen-of-ritonavir-darunavir-plus-dolutegravir-for-rescue-or-simplification-of-rescue-therapy-48%C3%A2-weeks-observational-data
#9
Amedeo F Capetti, Maria Vittoria Cossu, Giancarlo Orofino, Gaetana Sterrantino, Giovanni Cenderello, Giuseppe V De Socio, Anna Maria Cattelan, Alessandro Soria, Stefano Rusconi, Niccolò Riccardi, Gian Maria Baldin, Fosca P Niero, Giorgio Barbarini, Giuliano Rizzardini
BACKGROUND: Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. METHODS: All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight Italian centres were included in the analysis. The main metabolic data, efficacy parameters and safety data routinely collected were provided. This observational study is aimed to assess the efficacy of such approach...
September 30, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28948955/factors-affecting-high-density-lipoprotein-cholesterol-in-hiv-infected-patients-on-nevirapine-based-antiretroviral-therapy
#10
C Padmapriyadarsini, K Ramesh, L Sekar, Geetha Ramachandran, Devaraj Reddy, G Narendran, S Sekar, C Chandrasekar, D Anbarasu, Christine Wanke, Soumya Swaminathan
BACKGROUND & OBJECTIVES: Cardiovascular disease (CVD) risk with low high-density lipoprotein cholesterol (HDL-C) and high triglycerides is common in the general population in India. As nevirapine (NVP)-based antiretroviral therapy (ART) tends to increase HDL-C, gene polymorphisms associated with HDL-C metabolism in HIV-infected adults on stable NVP-based ART were studied. METHODS: A cross-sectional study was conducted between January 2013 and July 2014 among adults receiving NVP-based ART for 12-15 months...
May 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28945911/hdl-cholesterol-efflux-capacity-in-newly-diagnosed-hiv-and-effects-of-antiretroviral-therapy
#11
Mabel Toribio, Min Hi Park, Markella V Zanni, Gregory K Robbins, Tricia H Burdo, Kenneth C Williams, Meghan N Feldpausch, Lauren Stone, Kathleen Melbourne, Steven K Grinspoon, Michael L Fitzgerald
Context: In the general population, high-density lipoprotein (HDL) cholesterol efflux capacity (HCEC) relates inversely to incident cardiovascular events. Previous studies have suggested that HCEC is decreased in HIV and that antiretroviral therapy (ART) initiation might improve HCEC. Objective: To evaluate HCEC in the context of ART initiation and immune activation in HIV. Design and Outcome Measures: Baseline HCEC from 10 ART-naive HIV-infected males and 12 prospectively matched non-HIV-infected males were analyzed...
November 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28935146/effect-of-chocolate-and-mate-tea-on-the-lipid-profile-of-individuals-with-hiv-aids-on-antiretroviral-therapy-a-clinical-trial
#12
Suelen J Souza, Aline A Petrilli, Andrea M Teixeira, Patricia M Pontilho, Antonio A Carioca, Liania A Luzia, José M Souza, Nágila R Damasceno, Aluisio A Segurado, Patricia H Rondó
OBJECTIVE: HIV/AIDS is generally associated with dyslipidemia and oxidative imbalance, which are caused by the infection itself and by antiretroviral therapy (ART). The flavonoids, found in cocoa and yerba mate, have antioxidant and hypolipidemic properties. The aim of this study was to evaluate the effects of the consumption of dark chocolate and mate tea on the lipid profiles of individuals with HIV/AIDS who are undergoing ART. METHODS: A randomized, double-blind, placebo-controlled crossover clinical trial was conducted with 92 patients receiving ART for ≥6 mo and with viral suppression...
November 2017: Nutrition
https://www.readbyqxmd.com/read/28926407/dysfunctional-high-density-lipoprotein-from-hiv-individuals-promotes-monocyte-derived-foam-cell-formation-in-vitro
#13
Thomas A Angelovich, Anna C Hearps, Michael N Oda, Mark S Borja, Diana Huynh, Stefanie Homann, Anthony Jaworowski, Theodoros Kelesidis
OBJECTIVE: The role of high-density lipoprotein (HDL) function in HIV-related atherosclerotic cardiovascular disease (CVD) is unclear. HDLs isolated from HIV [HIV(+)HDL] and HIV-uninfected individuals [HIV(-)HDL] were assessed for HDL function and ability to promote monocyte-derived foam cell formation (MDFCF; a key event in HIV-related CVD) ex vivo. DESIGN/METHODS: Using an established in-vitro model of atherogenesis and plasma samples from an established cross-sectional study of virologically suppressed HIV men on stable effective antiretroviral therapy and with low CVD risk (median age: 42 years; n = 10), we explored the impact of native HDL [HIV(+)HDL] on MDFCF...
November 13, 2017: AIDS
https://www.readbyqxmd.com/read/28891536/urine-osmolality-in-treatment-na%C3%A3-ve-hiv-positive-subjects-in-southeast-nigeria
#14
E N Anyabolu, I I Chukwuonye, I Ezeani
BACKGROUND AND OBJECTIVES: Urine osmolality varies over a wide range of values in a healthy state. Dilute urine or concentrated urine may be observed in many environmental, physiologic, and disease conditions. Urine osmolality is not commonly evaluated in routine clinical practice and in human immunodeficiency virus (HIV) subjects. The factors that influence urine osmolality have not been completely identified. The aim of this study was to evaluate urine osmolality in treatment-naïve HIV subjects and to identify the factors that may influence dilute and concentrated urine in this group of patients...
August 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28857822/impact-of-protease-inhibitors-on-circulating-pcsk9-levels-in-hiv-infected-antiretroviral-naive-patients-from-an-ongoing-prospective-cohort
#15
Franck Boccara, Mathilde Ghislain, Laurence Meyer, Cecile Goujard, Cedric Le May, Corinne Vigouroux, Jean P Bastard, Soraya Fellahi, Jacqueline Capeau, Ariel Cohen, Bertrand Cariou
OBJECTIVE: The study aims to assess the association between proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of LDL cholesterol (LDL-C) homeostasis, and HIV-related dyslipidaemia in a cohort of HIV-positive (HIV+) patients under protease inhibitors. METHODS: Plasma PCSK9 levels were measured in 103 HIV+ patients before and after initiating protease inhibitor-based antiretroviral therapy (ART), and in 90 HIV-negative controls matched for age and sex...
November 13, 2017: AIDS
https://www.readbyqxmd.com/read/28810840/the-association-between-tuberculosis-and-the-development-of-insulin-resistance-in-adults-with-pulmonary-tuberculosis-in-the-western-sub-district-of-the-cape-metropole-region-south-africa-a-combined-cross-sectional-cohort-study
#16
Lauren Philips, Janicke Visser, Daan Nel, Renée Blaauw
BACKGROUND: The existence of a bi-directional relationship between tuberculosis (TB) and insulin resistance (IR)/diabetes has been alluded to in literature. Although diabetes has been linked to increased tuberculosis risk, the relationship between tuberculosis as a causative factor for IR remains unclear. The study aimed to determine if an association existed between tuberculosis and IR development in adults with newly diagnosed pulmonary tuberculosis at baseline. It was additionally aimed to document changes in IR status during TB follow-up periods...
August 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28791972/hcv-co-infection-is-associated-with-metabolic-abnormalities-among-haart-naive-hiv-infected-persons
#17
M A Kuti, J O Akinyemi, B O Ogunbosi, K M Kuti, O A Adesina, O A Awolude, O S Michael, I F Adewole
OBJECTIVES: To determine the metabolic abnormalities among Hepatitis C Virus (HCV) co infected HAART naïve HIV infected persons within the adult ARV clinic of the University College Hospital/University of Ibadan, Ibadan, Nigeria Methods: This was a retrospective study involving the review of clinical records of newly recruited HIV-infected persons in the adult antiretroviral (ARV) clinic over a 12 month period (January - December 2006). Baseline results for fasting plasma glucose (FPG) and fasting lipid profile were retrieved...
July 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28761616/cardiometabolic-risk-among-hiv-positive-ugandan-adults-prevalence-predictors-and-effect-of-long-term-antiretroviral-therapy
#18
Patrick Kazooba, Ivan Kasamba, Billy Nsubuga Mayanja, Joseph Lutaakome, Ivan Namakoola, Tino Salome, Pontiano Kaleebu, Paula Munderi
INTRODUCTION: We investigated the prevalence, predictors of and effect of Antiretroviral Therapy (ART) regimen on cardiometabolic risk among HIV-positive Ugandan adults at enrolment into a prospective cohort to study the Complications of Long-Term ART (CoLTART). METHODS: We collected data on cardiometabolic risk factors including dyslipidemia, hypertension, hyperglycemia, obesity and calculated the mean atherogenic index for Plasma (AIP) and 10 year Framingham risk score (FHS)...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28749986/the-role-of-the-tissue-factor-and-its-inhibitor-in-the-development-of-subclinical-atherosclerosis-in-people-living-with-hiv
#19
Katarzyna Barska, Wiesława Kwiatkowska, Brygida Knysz, Katarzyna Arczyńska, Maciej Karczewski, Wojciech Witkiewicz
INTRODUCTION: HIV infection is associated with an increased risk of cardiovascular disease in connection with atherosclerosis and thromboembolic complications. The pathogenesis of atherosclerosis is still unclear in this group of patients. Studies on pathogenesis of atherosclerosis in the general population emphasize the role of the extrinsic pathway of blood coagulation, particularly the tissue factor (TF) and tissue factor pathway inhibitor (TFPI). The effect of persistent activation of the immune system on enhanced expression of TF on the surface of monocytes in subjects infected with HIV is known to be correlated with the level of HIV RNA in blood serum...
2017: PloS One
https://www.readbyqxmd.com/read/28722790/switching-to-a-rilpivirine-emtricitabine-tenofovir-single-tablet-regimen-in-rna-suppressed-patients-infected-with-human-immunodeficiency-virus-1-effectiveness-safety-and-costs-at-96%C3%A2-weeks
#20
Paula Arrabal-Durán, Carmen G Rodríguez-González, Esther Chamorro-de-Vega, Paloma Gijón-Vidaurreta, Ana Herranz-Alonso, María Sanjurjo-Sáez
OBJECTIVES: This study evaluates the effectiveness, safety and costs of switching to a rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) regimen in treatment-experienced HIV-1-infected patients with sustained virological suppression. METHODS: Observational, prospective study. Study population included all treatment-experienced patients with sustained virological suppression who switched to RPV/FTC/TDF during 2013 in a tertiary hospital. Patients were followed until they completed 96 weeks of treatment...
August 2017: International Journal of Clinical Practice
keyword
keyword
30100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"